Chronic Stress Linked to Cancer Progression and Outcomes, Review Finds

A systematic review published in the International Journal of Molecular Sciences in 2026, prepared by researchers from Wroclaw Medical University, details the biological mechanisms linking chronic stress to cancer progression and treatment outcomes. The review analyzed data on breast, prostate, pancreatic, and ovarian cancers.

Chronic stress is defined biologically as a long-term strain on the body's adaptive capacity, where systems responding to threats remain active for extended periods. In oncology, stress encompasses anxiety, sadness, and social, professional, family, and existential factors.

The Stages Linking Chronic Stress to Cancer

The review outlines three related stages by which chronic stress influences cancer development and outcomes:

Persistent activation of the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system leads to sustained increases in cortisol, adrenaline, and noradrenaline levels. This state is associated with increased inflammation and immunosuppression, which may promote tumor progression and weaken treatment response.

Stress hormones can weaken immune surveillance and contribute to chronic, low-grade inflammation. This environment may facilitate cancer cell survival, multiplication, and evasion of control mechanisms.

Chronic stress may influence angiogenesis, cancer cell migration, and processes related to treatment resistance at the tissue level.

The authors note the difficulty in isolating the impact of stress from disease progression and treatment intensity in clinical trials.

Impact Varies by Cancer Type

The review indicates that chronic stress does not affect all cancers equally. Its significance depends on the cancer type and prognosis.

For cancers such as breast and prostate cancer, where survival rates are generally better, stress often presents as chronic uncertainty. Patients frequently experience long-term fear of recurrence and side effects. Biological roles of adrenergic and glucocorticoid signaling are highlighted, potentially influencing metastasis and therapy response in some patients.

In cancers with poorer prognoses, such as pancreatic and ovarian cancer, psychological distress and depression are more common and severe. Psychological symptoms can sometimes precede cancer diagnosis. In these cases, inflammatory and cytokine mechanisms, including elevated IL-6 levels, are prominent.

Psychotherapy's Role in Oncology

Psychological interventions in oncology have been shown to significantly benefit patients. These interventions:

• Reduce anxiety and depression.
• Improve quality of life.
• Affect stress and inflammation markers, such as cortisol levels and selected cytokines.

While these biological changes are observed, current knowledge does not establish a direct link between psychotherapy and increased survival. The effects of therapy may also diminish after completion, suggesting a need for sustained support.

Limitations and Recommendations

The review identifies several limitations, including heterogeneous stress measurement methods, a lack of meta-analyses for quantitative conclusions, and difficulty in separating stress as a biological factor from stress as a consequence of illness.

The authors conclude that chronic stress is a modifiable factor associated with measurable biological processes that should be addressed clinically. They propose a multi-faceted approach:

• Systematic integration of psycho-oncology into standard care.
• Routine distress screening and rapid assistance.
• Support for partners and caregivers.
• Development of digital interventions (e-health) and strategies to maintain therapeutic effects.

Chronic stress is emphasized as a modifiable risk factor to be analyzed within complex biological, psychological, and environmental interactions.